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Despite the presence of many therapeutic regimens like ima-
tinib and other tyrosine kinase inhibitors, the development of resis-
tance, intolerance, and side effects makes chronic myeloid leukemia
(CML) therapy challenging. Thus, there is a need to discover novel
drugs for CML patients. In this study, we attempted to assess
apigenin, a common plant dietary flavonoid, in terms of its cyto-
toxic, apoptotic, and cytostatic effects on imatinib-sensitive and
resistant Philadelphia-positive CML cells. We analyzed apigenin’s
effects on cell proliferation, apoptosis, caspase-3 activity, loss of
mitochondrial membrane potential, and cell cycle progression in
K562 and K562/IMA3 cells. Furthermore, we described genes and
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gene networks that are modulated in CML in response to apigenin.
Results of our study revealed that apigenin has cytotoxic and apop-
totic effects on both cell types. We also displayed that apigenin in-
duced G2/M arrest in K562 cells while arresting K562/IMA3 cells
in S phase especially at the highest apigenin concentration. The
expression analysis identified a set of genes that were regulated
by apigenin in K652 and K562/IMA3 cells. Association of mod-
ulated genes with biological functional groups identified several
networks affected by apigenin including cell survival, prolifera-
tion, cell death, cell cycle, and cell signalling pathways.
INTRODUCTION
Chronic myeloid leukemia (CML), a hematological disor-
der, is defined by a reciprocal translocation between the break-
point cluster (BCR) gene on chromosome 22 and the abelson
leukemia virus oncogene (ABL) gene on chromosome 9 (1).
BCR-ABL1 fusion gene encoding the chimeric BCR-ABL1
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oncoprotein with constitutive tyrosine kinase activity has been
generated as a molecular consequence of this translocation (1).
The exact role of BCR-ABL protein in myeloid proliferation and
transformation in CML has been studied in several in vivo and in
vitro models of tumor development (2). Oncogenic BCR-ABL
has been shown to possess antiapoptotic activity (3). BCR-ABL
triggers the activation of many signaling pathways by inter-
acting with several effector molecules and promotes prolifer-
ation and genetic instability while suppressing apoptosis and
weakening cellular adhesion (4). In the clinic, tyrosine kinase
inhibitors (TKIs) are used for the treatment of CML and con-
tribute the quality of patient’s life (5). Imatinib mesylate, a
first-generation tyrosine kinase inhibitor, is used for first-line
therapy in CML due to its great efficacy (6). Despite its thera-
peutic efficacy, the development of imatinib-resistance and in-
tolerance is still a challenging problem for most patients (7).
Many novel compounds and therapeutic approaches are cur-
rently being investigated preclinically and clinically to over-
come imatinib resistance (8). Dasatinib and nilotinib are the
second generation TKIs that are more effective and safer in pa-
tients with imatinib-resistance and intolerance (8). However, the
development of novel Bcr-Abl mutants resistant to these new
small-molecule inhibitors and adverse effects of these agents
are still significant problems (9).Therefore, alternative thera-
peutic approaches are required and natural products have been
investigated because of their potential in cancer prevention and
treatment.
Flavonoids are a family of polyphenolic compounds that are
common components of the human diet. They are widely dis-
tributed in the plant kingdom and occur naturally in a broad
range of fruits and vegetables. Currently, there is a growing
interest in polyphenolic phytochemicals, including flavonoids,
because experimental and epidemiological data support that
they exert many beneficial effects including antioxidant, anti-
inflammatory, cardioprotective, and anticarcinogenic activities
(10–12). Apigenin (4’,5,7- trihydroxyflavone), a common plant
dietary flavonoid, is present at high levels in several fruits and
vegetables, has been paid attention as an alternative anticancer
compound, but its mechanism of action remains unclear and
shows variation between different cancer types (13). The mech-
anisms of apigenin-induced apoptosis include stimulation of gap
junctional communication, inhibition of transformation, angio-
genesis, and activation of nuclear transcription factor kappa B
(NF-κB) (14). Morover, apigenin has been reported to induce
apoptosis through caspase-3, -8, and -9 (15–17). Apigenin treat-
ment has been also shown to alter the Bax/Bcl-2 ratio in favor of
apoptosis (11,12). The growth inhibitory and apoptotic effects
of apigenin on several human cancer types, including breast,
lung, colon, liver, and certain hematologic cancer cells have
been studied (18–20), but there is a lack of studies related with
the effects of apigenin in CML.
Herein, we aim to examine the cytotoxic, apoptotic, and cy-
tostatic effects of apigenin on imatinib-sensitive and resistant,
Philadelphia-positive K562 CML cells. In the present article we
also describe genes and networks that are modulated in CML
following treatment with apigenin.
MATERIALS AND METHODS
Chemicals
Apigenin was obtained from Santa Cruz Biotechnology, Inc.
(Heidelberg, Germany). The stock solution of apigenin was
dissolved in dimethylsulfoxide (DMSO) at a concentration of
10 mM, stored at −20◦C, and diluted in blank cell culture
medium. The final concentration of DMSO did not exceed more
than 0.1% in culture. Penicillin-streptomycin, RPMI 1640, and
fetal bovine serum were obtained from Invitrogen (Paisley, UK).
Cell Lines and Culture Conditions
Human K562 CML cells were obtained from German Col-
lection of Microorganisms and Cell Cultures (Braunschweig,
Germany). K562 cells were maintained in RPMI 1640 growth
medium containing 10 % fetal bovine serum and 1% penicillin-
streptomycin at 37◦C in 5% CO2. K562 cells grown in RPMI
1640 were exposed to increasing concentrations of imatinib,
starting with 50 nM. At the end of this process, 3 μM ima-
tinib resistant cells were generated and named as K562/IMA3
cells (21).
Measurement of Cell Growth by MTT Assay
Antiproliferative effects of apigenin on K562 and
K562/IMA3 CML cells was determined by MTT cell prolifera-
tion assay. In short, 2 × 104 cells/well were seeded into 96-well
plates containing 100 μl of the growth medium in the absence
or presence of increasing concentrations of apigenin and then
incubated at 37◦C in 5% CO2 for 48 and 72 h. After incubation
period, the cells were treated with 20 μl MTT for 3 h. Then,
plates were centrifuged for 10 min at 580 g. After centrifuga-
tion, supernatants were removed from the plates and then the
MTT crystals were homogenized by adding 100 μl DMSO into
each well. To homogenize the pellets more efficiently, the plates
were shaken for 5 min by shaker. Afterwards, the plates were
read under 570 nm wavelengths by Elisa reader (Thermo Elec-
tron Corporation Multiskan Spectrum, Vantaa, Finland). Finally,
IC50 value (drug concentration inhibits cell growth by 50%) of
apigenin was calculated according to the cell proliferation plots
(22).
Analysis of Apoptotic Cells by AnnexinV-FITC/PI
Double Staining
We determined the translocation of phosphatidylserine from
the inner membrane to the outer cell membrane in order to ex-
amine apoptotic effects of apigenin on both sensitive and ima-
tinib-resistant CML cells. Initially, 1 × 106 cells were treated
with different concentrations of apigenin for 72 h. After incuba-
tion period, the cells were washed twice with cold PBS and then
homogenized with 1 mL of 1X binding buffer. Then, 100 μl
of this solution were added into glass tubes. 5 μl of FITC An-
nexin V and 5 μl of propidium iodide (PI) were added onto
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the cell solutions. These samples were vortexed gently and then
incubated for 15 min at room temperature in the dark. After-
wards, 400 μl of 1X binding buffer were added to each tube,
and then they were analyzed by flow cytometry (BD Facscanto
Flowcytometry, Erembodegem, Belgium) within 1 h.
Analysis of the Changes in Mitochondrial Membrane
Potential
We examined the loss of mitochondrial membrane potential
(MMP) in response to apigenin in both cells by JC-1 Mitochon-
drial Membrane Potential Detection Kit (Cayman Chemicals,
Ann Arbor, MI). This kit uses a unique cationic dye, JC-1,
to signal the loss of MMP. JC-1 accumulates in mitochondria,
which stain red in nonapoptotic cells while in apoptotic cells,
MMP collapses, and thus JC-1 dye remains in the cytoplasm
as a monomer that stains green under fluorescent light. Briefly,
the cells (1 × 106 cells/2 mL), induced to undergo apoptosis,
were collected by centrifugation at 400 g for 10 min. Super-
natants were removed and pellets were homogenized by 300 μl
of medium. Thirty μl of JC-1 dye were added onto the cells and
the cells were incubated at 37◦C in 5% CO2 for 30 min. Then,
they were centrifuged at 400 g for 5 min, supernatants were
removed and 200 μl of assay buffer were added onto the pellets
and vortexed. Then, this step was repeated once again. After-
wards, all pellets were homogenized with 320 μl assay buffer
and 100 μl from each of them were added into 96-well plate
as triplicates. The aggregate red form has absorption/emission
maxima of 560/595 nm, whereas the monomeric green form
has absorption/emission maxima of 485/535 nm. The plate was
read in these wavelengths by fluorescence Elisa reader (Thermo
Varioskan Spectrum, Finland). At the end, the ratio of fluores-
cent intensity of JC-1 monomers (green) to fluorescent intensity
of JC-1 aggregates (red) were calculated for each concentration
as well as untreated control sample. Then, relative changes in
cytoplasmic/mitochondrial JC-1 were determined by comparing
to control samples (23).
Analysis of Caspase-3 Activity
Changes in caspase-3 activity of the cells were examined by
caspase-3 colorimetric assay kit (BioVision Research Products,
Milpitas, CA). This assay is based on spectrophotometric de-
tection of the chromophore p-nitroanilide (pNA) after cleavage
from the labeled substrate DEVD-pNA that can be recognized by
caspases. In short, the cells (1 × 106 cells/2 mL/well), induced
to undergo apoptosis by apigenin, were collected by centrifuga-
tion at 400 g for 10 min. The cells were lysed by adding 50 μl
of chilled Cell Lysis Buffer and incubated on ice for 10 min
before centrifugation at 10,000 g for 1 min. Supernatants were
transferred to new eppendorf tubes and the reaction mixture
was prepared in 96-well plates by adding 50 μl of 2X Reaction
Buffer (containing 10 mM DTT), 50 μl of sample, and 5 μl
of DEVD-pNA substrate and incubated for 2 h at 37◦C in CO2
incubator. At the end of this period, the plate was read under
405 nm wavelengths by Elisa reader (Thermo Electron Corpo-
ration Multiskan Spectrum, Vantaa, Finland). The absorbance
values were normalized to protein concentrations determined
by Bradford assay.
Cell Cycle Analysis
This technique is based on the determination of amounts
of dsDNA by using PI, a DNA-binding dye, through flow cy-
tometry. When the data acquired from the flow cytometry are
analyzed, cell cycle phases and the amounts of fragmented DNA
of the cells can be determined. Briefly, 1 × 106 cells/2 mL were
treated with increasing concentrations of apigenin for 72 h. After
the incubation period, cells were collected by centrifugation at
400 g for 10 min. Supernatants were removed, and pellets were
homogenized with 1 mL cold PBS, and then the samples were
put on ice. Afterwards, although the cells were slightly vortexed,
4 mL of cold ethanol were added onto these cells, and then put
on ice. Fixated cells by this method were incubated overnight
at −20◦C for the analysis. Next day, the cells were centrifuged
at 400 g for 10 min, and supernatants were completely removed
from the pellets. Pellets were homogenized with 1 mL cold PBS,
and centrifuged again at 400 g for 10 min. Afterwards, cell pel-
lets were homogenized with 1 mL PBS containing 0.1% triton
X-100, and then 100 μl RNase A (200 μg/mL) were added onto
these cells, and they were incubated at 37◦C for 30 min. After
this incubation period, 100 μl PI (1 mg/mL) were added onto
the cells. These cells were incubated at room temperature for
15 min and then analyzed by flow cytometry.
Microarray Analysis
Total RNA was isolated from K562 and K562/IMA3 cells ex-
posed to 50 μM and 100 μM Apigenin for 72 h using High Pure
RNA Isolation Kit (Roche, San Francisco, CA) according to
manufacturer’s instructions. The concentrations and purities of
RNA samples were measured with NanoDrop (Thermo Scien-
tific, Wilmington, DE) spectrophotometer (260/280 nm ratios)
and only the samples with an A260/A280 ratio between 1.9 and
2.1 were considered for further use. Illumina Human HT-12v4
beadchip microarrays (containing ∼47,000 transcripts: ∼30000
genes) (Illumina, Inc., San Diego, CA) were used to assess
global gene expression for each sample. Five hundred ng of
total RNA were firstly reverse-transcribed into cDNA and then
cDNA samples were converted to biotin-labeled cRNA by using
the Illumina TotalPrep RNA-amplification kit (Ambion, Foster
City, CA) based on manufacturer’s instructions for hybridization
analysis. Then, 1.5 μg of labeled cRNA was hybridized to each
array according to the Illumina whole-genome gene expression
direct hybridization assay protocol. Arrays were scanned using
the Illumina BeadArray Reader. The images were processed and
converted into signal intensities using the Illumina GenomeStu-
dio software (Illumina, Inc., San Diego, CA). The same software
was used to perform hybridization quality control (QC).
Statistical Analysis
Statistical significance was determined using one-way analy-
sis of variance (ANOVA) for MTT analyses, and 2-way ANOVA
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for Annexin V, MMP, and caspase-3 activity analyses. P < 0.05
was considered to be significant. The signal intensities corre-
sponding to gene expression levels were background corrected
and imported into text files using the Illumina GenomeStu-
dio. Hierarchical cluster analysis was applied to data sets to
evaluate the “proximity” between genes and hierarchical clus-
ters were constructed with the statistically significant (P <
0.05) genes. Genes were considered differentially expressed
when logarithmic gene expression ratios in 3 independent hy-
bridizations were more than 1.5 or less than 0.66 and when
the P values were less than 0.05. Gene ontology and path-
way analyses were performed to consider biological meaning of
differential expression of genes between the treated and un-
treated samples by using the Kyoto Encyclopedia of Genes
and Genomes and Ingenuity Pathway Analysis (IPA; Ingenuity
Systems, Redwood City, CA).
RESULTS
Cytotoxic Effects of Apigenin on Both K562 and K562/
IMA3 Cells
Our previous findings demonstrated that K562/IMA3 cells
(IC50: 14680 nM) were around 52-fold more resistant to ima-
tinib as compared to sensitive K562 cells (IC50: 280 nM) (21).
Cytotoxic effects of apigenin on K562 and K562/IMA3 cells
were determined by MTT cell proliferation assay. IC50 values
of apigenin for K562 cells at 48 and 72 h were calculated from
cell proliferation plots and were found to be 16 and 2,5 μM, re-
spectively (Fig. 1A). On the other hand, IC50 values of apigenin
for K562/IMA3 cells were found to be 65 and 63 μM at indicated
time points, respectively (Fig. 1B). These results demonstrated
that apigenin has cytotoxic effects on both cell types in a time-
and dose-dependent manner. However, K562/IMA3 cells were
4- and 25-fold more resistant to apigenin as compared to K562
cells at 48 and 72 h, respectively.
Apigenin Induces Apoptosis of Both K562 and K562/
IMA3 Cells in a Dose-Dependent Manner
Apoptotic effects of apigenin on both cells were determined
by Anexin-V/PI double staining. The percentage of apoptotic
cell population of sensitive and resistant cells treated with in-
creasing concentrations of apigenin was determined by flow
cytometry. Although no significant changes were detected in
apoptotic cells up to 20 μM apigenin, there were 2.6- and 4.2-
fold increases in percentage of apoptotic K562 cells in response
to 50 and 100 μM apigenin, respectively, as compared to un-
treated controls (Fig. 2A and Fig. 2B). On the other hand, 50
and 100 μM apigenin caused 1.1- and 2.2- fold increases in
apoptotic K562/IMA3 cell population (Fig. 2C and 2D). These
results indicated that apigenin increased apoptotic cell popula-
tion at higher concentrations in both cell lines but K562/IMA3
cells showed resistance to apigenin as compared to K562 cells.
Apigenin Induces Loss of MMP in Both K562 and K562/
IMA3 Cells in a Dose-Dependent Manner
Loss of mitochondrial membrane potential is an important
sign of apoptosis because it has been linked to initiation and acti-
vation of apoptotic cascades. Therefore, we determined whether
apigenin causes the loss of MMP in both cell lines exposed
to the same concentrations of apigenin. The results revealed
that there were 1.3-, 1.7-, 2-, 2.1-, and 2.3-fold increases in
loss of MMP in K562 cells treated with 5, 10, 20, 50, and
100 μM apigenin, respectively, as compared to untreated con-
trols. The same concentrations of apigenin led to 1.18-, 1.19-,
1.24, 1.3, and 1.41-fold increases in loss of MMP in K562/
IMA3 cells, respectively, as compared to untreated controls
(Fig. 3).
Apigenin Increases Caspase-3 Activity in a Dose-
Dependent Manner in Both K562 and K562/IMA3 Cells
Caspase-3 enzyme has a central role in the mitochondrial-
mediated cell death. To determine whether apoptosis induced
by apigenin was associated with activation of caspase-3, the
cells were treated with increasing concentrations of apigenin
for 72 h and the changes in caspase-3 enzyme activity was
detected through the cleavage of the labeled substrate DEVD-
pNA. There were 1.02-, 1.2-, 1.26-, and 1.9-fold increases in
caspase-3 enzyme activity in response to 5, 10, 20, and 50 μM
apigenin in K562 cells, respectively, as compared to untreated
controls (Fig. 4A). On the other hand, the same concentrations
of apigenin increased caspase-3 enzyme activity 1.07-, 1.08-,
1.28, and 1.54-fold in K562/IMA3 cells exposed to the same
concentrations of apigenin as compared to control, respectively
(Fig. 4B). K562/IMA3 cells were also treated with 100 μM api-
genin and there was only a 1.86-fold increase in caspase-3 activ-
ity. Apigenin increased caspase-3 activity in a dose-dependent
manner with no significant changes in K562 and K562/IMA3
cells.
Apigenin Arrested Cell Cycle Progression in G2/M Phase
in K562 Cells but not in K562/IMA3 Cells
To determine the possible mechanism of antiproliferative
activity of apigenin, cell cycle progression of both cell lines
were examined by flow cytometry in the presence of DNase
free RNase and PI dye. As summarized in Fig. 5A, treatment
of K562 cells with apigenin resulted in small increases in the
percentage of cells in the G2/M phase at 5 to 20 μM apigenin
but in response to 100 μM apigenin there was a significant
increase. In accordance with this result, there were also de-
creases in the percentage of the cells in G0/G1 and S phases.
On the other hand, there was no significant effect of apigenin
on G2/M phase of K562/IMA3 cell cycle (Fig. 5B). However,
K562/IMA3 cells arrested in S phase especially at 100 μM
apigenin.
APIGENIN FOR IMATINIB-SENSITIVE AND RESISTANT CML 603
FIG. 1. Cytotoxic effects of apigenin on human K562 (A) and K562/IMA3 (B) chronic myeloid leukemia (CML) cells. The IC50 value of apigenin was calculated
from cell proliferation plots. The results are the means of 3 independent experiments. The error bars represent the standard deviations. Statistical significance was
determined using one-way analysis of variance and P < 0.05 was considered to be significant.
Identification of Genes Differentially Expressed
in Apigenin Treated Imatinib-Sensitive and Resistant
CML Cells
We examined the changes in expression levels of the genes
following treatment of K562 and K562/IMA3 cells with 50
and 100 μM apigenin. Isolated total RNA was amplified and
converted to biotin-labeled cRNA, which was hybridized to
microarray system containing approximately 30,000 genes.
Hierarchical clustering of gene expression (heat map analysis)
in untreated and apigenin treated K562 and K562/IMA3 cells
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FIG. 2. Evaluation of apoptosis in sensitive and resistant cells induced by apigenin. The percentage of cells undergoing apoptosis in a dose-dependent manner
as compared to control and FACS analysis via Annexin V-FITC/propidium iodide (PI) staining (A and B for K562 cells, C and D for K562/IMA3 cells). Cells in
the lower right quadrant indicate Annexin-positive/PI negative, early apoptotic cells. The cells in the upper right quadrant indicate Annexin-positive/PI positive.
The percentage of cells annexin V positive, PI positive, or double positive for both annexin V and PI is indicated. The results are the means of 3 independent
experiments. (Color figure available online.)
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FIG. 2. (Continued)
is shown in Fig. 6A. total of 1526 and 1368 genes were
significantly regulated (P < 0.05) in 50 and 100 μM apigenin
treated K562 sensitive cells, respectively. The number of genes
upregulated were 674 whereas those of downregulated were
852 in 50 μM apigenin-treated K562 cells. In 100 μM apigenin
treated K562 cells, 676 genes were upregulated and 692 genes
were downregulated. Moreover, a total of 315 genes were com-
mon between 50 and 100 μM apigenin-treated sensitive cells.
On the other hand, a total of 1485 (778 genes upregulated, 707
downregulated) and 2442 genes (1176 genes were upregulated,
1266 genes were downregulated) were significantly changed
(P < 0.05) in response to 50 and 100 μM apigenin in
K563/IMA-3 cells, respectively. A total of 455 genes were
common between 50 and 100 μM apigenin-treated imatinib
resistant cells. Fold-change analysis showed that UNC5A
(netrin receptor), PDCD1LG2 (programmed cell death 1 ligand
2), BCAM (basal adhesion molecule), SCARA5 (scavenger
receptor class A, member 5), and DGKA (diacylglycerol
kinase alpha) were the examples of altered genes in both
50 and 100 μM apigenin treated sensitive cells (Table 1).
Table 2 illustrates the examples of genes altered after apigenin
treatment in K562/IMA3 cells. It was clear that HAGH
(hydroxyacylglutathione hydrolase or glyoxylase II), IL15RA
(interleukin 15 receptor, alpha), ENTPD1 (ectonucleoside
triphosphate diphosphohydrolase 1), and DGKI (diacylglycerol
kinase iota) were the examples of upregulated genes in both 50
and 100 μM apigenin-treated K562/IMA3 cells.
Identification of Genetic Networks Affected by Apigenin
To examine the affected genetic networks after apigenin
treatment, we carried out pathway analysis using the IPA tool.
These networks describe functional relationships between gene
606 S. SOLMAZ ET AL.
TABLE 1
The genes altered ≥twofold after apigenin treatment of K562
sensitive cells
Altered genes in 50 μM
apigenin-treated K562
sensitive cells (Fold changes)
Altered genes in 100 μM
apigenin-treated K562
sensitive cells (Fold changes)
UNC5A (42.440) UNC5A(32.340)
PDCD1LG2 (16.818) PDCD1LG2(18.015)
HES2 (5.659) BCAM(5.044)
BCAM (4.226) SNAI1(4.777)
NPTX1 (4.201) MOB4(4.272)
SCARA5 (3.957) LOXL4(3.477)
PRKAG2 (2.982) SCARA5(3.181)
miR-15 (2.049) miR − 195(2.782)
PCSK6 (-24.088) ADAMTS13(2.266)
KIF12 (-8.070) PPP1R9A(−31.415)
EIF3C/EIF3CL(-7.747) CD74(−14.305)
UGT1A6 (-6.812) EPHA5(−4.640)
REPS2 (-5.261) BRAF(−2.076)
CALML6 (-2.559) FYN(−2.313)
PRKCB (-2.285) IL8(−2.456)
DGKA (-2.179) DGKA(−2.288)
Boldface type represents some genes induced in both 50 and
100 μM apigenin-treated K562 cells.
TABLE 2
The genes altered twofold after apigenin treatment of
K562/IMA3 imatinib resistant cells
Altered genes in 50 μM
apigenin treated K562/IMA-3
cells (fold changes)
Altered genes in 100 μM
apigenin treated K562/IMA-3
cells (fold changes)
HAGH (21.248) HAGH(22.630)
IL15RA (18.2591) IL15RA(10.215)
ENTPD1 (7.485) DISC1(6.221)
TRAF5 (5.634) ATR(6.018)
DISC1 (5.593) ENTPD1(5.906)
RPE65 (5.380) CHEK2(3.992)
MEX3D (5.203) MRP6(3.203)
ITGB5 (4.768) MMP17(3.171)
DGKI (2.574) DGKI(2.318)
MAL2 (-27.736) CYP4Z1(−12.850)
BCAS1 (-12.817) CD86(−8.729)
RHOBTB1 (-4.728) GAB1(−6.585)
MMRN1 (-3.910) CXCR4(−5.804)
FOXA2 (-3.785) PCNA(−2.299)
PKIG (-2.962) SCARA5(−2.469)
Boldface type represents some genes induced in both 50 and
100 μM apigenin-treated K562/IMA3 cells.
FIG. 3. Percent changes in cytoplasmic/mitochondrial JC-1 in K562 and K562/IMA3 cells treated with increasing concentrations of apigenin. The results are the
means of 3 independent experiments. The error bars represent the standard deviations. Statistical significance was determined using 2-way analysis of variance
and P < 0.05 was considered to be significant.
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FIG. 4. Changes in caspase-3 enzyme activiy in K562 (A) and K562/IMA3 cells (B) in response to apigenin. The results are the means of 3 independent
experiments. The error bars represent the standard deviations. Statistical significance was determined using 2-way analysis of variance and P < 0.05 was
considered to be significant.
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FIG. 5. Effect of apigenin on cell cycle progression. The percentage of cells in cell cycle phases are shown in the graphs (A and B). The results are the means of
3 independent experiments. Statistical significance was determined using 2-way analysis of variance and P < 0.05 was considered to be significant.
products based on known interactions in the literature. The re-
sults showed that cancer (P value = 1.01E-05 – 3.82E-02) was
the most significant network with 310 affected molecules in
50 μM apigenin-treated K562 imatinib sensitive cells. More-
over, cell death and survival with 271 molecules (P value
= 5.59E-05 – 3.97E-02) and cellular development with 242
molecules (P value = 1.52E-04 – 3.62E-02) were the other
most affected networks in 50 μM apigenin treated K562 cells.
Similarly, the most affected network in 100 μM apigenin treated
K562 cells was the cancer with 280 molecules (P value = 2.78E-
04 – 3.34E-02). Cell-to-cell signaling and interaction (P value =
1.32E-04 – 3.30E-02) with 90 molecules and hematological sys-
tem development and function (P value = 1.89E-04 – 3.32E-02)
with 154 molecules were affected as well as cancer network. On
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FIG. 6. Hierarchical clustering based on gene expression data from K562 and K562/IMA3 cells exposed to apigenin. Comparison between K562/IMA3 cells
treated with 50 μM (A) and 100 μM (B) apigenin. Comparison between K562 cells treated with 50 μM (C) and 100 μM (D) apigenin. A fold-change ratio was
calculated using the treated sample and its matched untreated sample. Green is downregulated genes and red is upregulated genes. (Color figure available online.)
the other hand, cell-to-cell signaling and interaction (P value =
1.25E-06 – 9.57E-03), cellular growth and proliferation (P value
= 1.06E-05 – 9.57E-03) and cell signalling (P value = 1.38E-05
– 9.52E-03) were the significantly altered networks with 155,
109, and 84 molecules, respectively, in 50 μM apigenin-treated
K562/IMA3 cells (Fig. 6). In K562/IMA3 cells treated with
100 μM apigenin, cancer (P value = 1.50E-06 – 2.17E-02), cel-
lular death and survival (P value = 8.84E-05 – 2.16E-02), cell
cycle (P value = 1.06E-05 – 2.21E-02) and hematological sys-
tem development and function (P value: 1.74E-05 – 2.21E-02)
were changed networks with 511, 443, 112, and 225 molecules,
respectively (Fig. 6).
DISCUSSION
Flavonoids are essential constituents of the human diet and
have been suggested to possess anticarcinogenic properties (19).
Recently, apigenin, a naturally occurring plant flavone, have
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been found to induce apoptosis in various tumor cells includ-
ing breast, cervical, lung, ovarian, prostate, liver, and certain
leukemias (12). Apigenin induces cell death with variable ef-
ficacy in several cancer types including colon, breast cancer,
and prostate cancer. Despite its low efficacy in epithelial cells,
apigenin induces apoptosis with high efficacy in myelogenous
leukemia cells. However, the mechanisms regulating apigenin-
induced apoptosis in leukemia cells remain elusive (13,19). In
recent studies, apigenin has been shown to trigger apoptosis
through Hsp27 phosphorylation (20), cytochrome c release (19),
caspase activation (16,19), and proteasome inhibition in sev-
eral leukemic cells (24). We conducted this study to examine
the cytotoxic, cytostatic, and apoptotic effects of apigenin on
K562 and K562/IMA3 CML cells. We treated the cells with
increasing concentrations of apigenin and determined its cyto-
toxic/antiproliferative effects by MTT cell proliferation assay.
The results of this assay revealed that apigenin decreased pro-
liferation of the cells in a dose- and time-dependent manner. It
is very well known in the literatu¨re that cancer cells resistant to
any agent may show cross resistance to the others. However, the
important point in this study is that although K562/IMA-3 cells
are more than around 50 times resistance to imatinib as com-
pared to sensitive cells, they are just 4 times more resistance
to apigenin at 48 h. On the other hand, Annexin-V/PI double
staining showed increases in apoptotic cell population in both
K562 and K52/IMA-3 cells in response to 50 and 100 μM api-
genin as compared to untreated controls. However, K562/IMA3
cells showed resistance to apigenin as compared to K562 cells
because, only 1.1- and 2.2-fold increases have been detected in
apoptotic K562/IMA3 cell population, whereas there were 2.6-
and 4.2-fold increases in percentage of apoptotic K562 cells. To
elucidate the molecular mechanism of apigenin induced apopto-
sis in imatinib-sensitive and resistant cells, we first checked the
effect of apigenin on MMP. The JC-1 dye-based assay results
revealed that apigenin caused loss of MMP in a dose-dependent
manner in both cells. It is very well known that mitochondria is
an important player for all apoptotic pathways and it is widely
accepted that alterations in the structure and function of mito-
chondria play an important role in caspase-dependent apoptosis.
Caspase-3 functions in the last step of caspase-mediated apopto-
sis and is responsible for the properties of apoptotic cells (such
as DNA fragmentation) (19). Based on this knowledge, we next
checked the activation of caspase-3 enzyme in apigenin treated
cells. Our data demonstrated that apigenin increased caspase-3
activities of both cell types in a dose-dependent manner as com-
pared to untreated controls. Taken together, we can conclude that
apigenin may induce apoptosis in both cells through the loss of
MMP and caspase-3 activation. However, it was clearly indi-
cated in this study that K562/IMA3 cells required higher doses
of apigenin than K562 cells for antiproliferative and apoptotic
effects. Similar to our results, apigenin was shown to induce
mitochondial depolarization and caspase activation in HL-60
acute promyelocytic leukemia cells (16). We also investigated
the cytostatic property of apigenin on CML cells and observed
that the treatment of K562 CML cells with apigenin resulted in
G2/M phase arrest especially at high concentrations. Many stud-
ies have reported that apigenin blocks cell cycle progression in
cancer cells, however, depending on the cell type, apigenin can
arrest the cell cycle in different phases. For instance, it caused
G2/M arrest in colon carcinoma (25). Nevertheless, in human
prostate cancer, LNCap and PC-3 cells, apigenin induced cell
cycle arrest in G0/G1 (26). The results of our study extend these
observations that, depending on the cyclins affected, responses
may be substantially different.
In this study, we also performed microarray analysis in K562
and K562/IMA3 cells to identify the genes and networks that are
involved in apigenin-induced apoptosis. For this purpose, heat
map analysis was performed to cluster the genes in K562 and
K562/IMA3 cells exposed to 50 and 100 μM apigenin. As in-
dicated in the result part, both cell types responded to apigenin
with changes in the expression levels and numbers of genes.
Moreover, the number of altered genes showed differences be-
tween 50 and 100 μM apigenin-treated cells while there were
some common genes. For instance, UNC5A and SCARA5 were
some common altered genes with different expression levels in
50 and 100 μM apigenin-treated K562 cells. UNC5A is associ-
ated with tumorigenesis in nonneuronal cells and function as a
tumor supressor (27,28). Several studies showed that UNC5A is
downregulated in human breast, lung, and colorecteral cancers
and it was found to induce apoptosis in p53-dependent manner
(28, 29). In our study, this gene was the most upregulated one
in both 50 and 100 μM apigenin-treated K562 cells and it could
be tought to cause apigenin induced cell death. Similarly, it is
known that SCARA5 gene has tumor suppressor function (30)
and its upregulation could be related to apigenin mediated cell
death in K562 cells. Besides UNC5A and SCARA5, genes sum-
marized in Table 1 have been shown to possess different roles
in carcinogenesis depending on their expression status (31–33).
The study also concluded that apigenin treatment could mod-
ulate the phosphatidylinositol signaling system, which has key
regulatory functions in cell survival, proliferation, and apopto-
sis, in both 50 and 100 μM apigenin-treated K562 cells due to
downregulation of some players of this pathway such as DGKA
in response to apigenin treatment. Therefore, the downregula-
tion of this pathway could be responsible for apigenin-mediated
apoptosis of K562 cells. On the other hand, apigenin treatment
altered the expression levels of several genes in K562/IMA3
cells as compared to untreated controls (summarized in
Table 2). For example, HAGH gene, encoding glyoxylase II
enzyme (which is a member of glyoxalase pathway), was the
most upregulated one in both 50 and 100 μM apigenin treated
K562/IMA3 cells and it is known that the overexpression of this
gene is related to drug and apoptosis resistance in several cancer
cells such as leukemia, lung, and breast cancer (34). Therefore,
K562/IMA3 cells might show resistance to apigenin-induced
apoptosis as compared to sensitive K562 cells due to overex-
pression of HAGH. Similarly, IL15RA and ENTPD1 were the
examples of overexpressed genes in K562/IMA3 cells and their
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upregulation is known to induce growth and proliferation of can-
cer cells (35,36). Based on this knowledge, we concluded that
their upregulation might be responsible for survival of the re-
sistant cells after apigenin treatment. In contrast to K562 cells,
phosphatidylinositol signaling system was thought to be acti-
vated following apigenin treatment in K652/IMA-3 cells since
DGKI, downstream player in this pathway, was upregulated
in 50 and 100 μM apigenin treatment. DGKI overexpression
has been displayed to induce cell growth (37) and its modula-
tion might be related to lower apoptotic effect of apigenin on
K562/IMA3 cells. Besides the above genes, genes summarized
in Table 2 have been shown to be related with tumor growth and
drug resistance depending on their expression status (30,38,39).
As explained in the Results section, K562/IMA3 cells were more
resistant to apigenin treatment than K562 cells in terms of cyto-
toxic and apoptotic effects and microarray data supported these
results. Therefore, discussed genes in K562 and K562/IMA3
cells may warrant further investigation as a candidate target of
apigenin. In addition to gene clustering, IPA tools were used
to get an idea about networks with known biological pathways.
These networks were found to be associated with the cell sur-
vival, proliferation, cell death, cell cycle, and cell signalling
pathways. Apigenin might display its anticarcinogenic property
in several cancer types by modulating cell signalling pathways
such as phosphatidylinositol 3-Kinase/Akt-dependent pathway,
MAPK pathway, and cell cycle related pathways (12).
In conclusion, the results of this study indicated that api-
genin may have therapeutic potential in imatinib-sensitive and
imatinib-resistant CML cells due to induction of apoptosis, in-
hibition of cell proliferation and cell-cyle arrest. Moreover, the
genetic networks derived from this study illuminate some of
the biological pathways affected by apigenin treatment while
providing a proof of principle for identifying candidate genes
that might be targeted for CML therapy. Furthermore, in vivo
administration of most effective concentrations of apigenin into
K562 mice xenografts could be helpful to understand the possi-
bility that apigenin may have clinical implications and might be
further tested for incorporating in leukemia treatment regimens.
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